Literature DB >> 15812146

Modification of collagen matrices for enhancing angiogenesis.

Chang Yao1, Pascale Prével, Sabine Koch, Peter Schenck, Ernst Magnus Noah, Norbert Pallua, Guy Steffens.   

Abstract

The vascularization of engineered tissues in many cases does not keep up with the ingrowth of cells. Nutrient and oxygen supply are not sufficient, which ultimately leads to the death of the invading cells. The enhancement of the angiogenic capabilities of engineered tissues therefore represents a major challenge in the field of tissue engineering. The immobilization of angiogenic growth factors may be useful for enhancing angiogenesis. The most potent angiogenic growth factor specific to endothelial cells, vascular endothelial growth factor (VEGF), occurs in several splice variants. The variant with 165 amino acids both has a high angiogenic activity and a high affinity for heparin. We therefore incorporated heparin molecules into collagen matrices by covalently cross-linking them to amino functions on the collagen. Physical binding of VEGF to the heparin may then prevent a rapid clearance from the implant, while the release rate may become coupled to the degradation of the collagen matrix. The modified matrices were characterized by determination of the extent of the heparin immobilization, the in vitro degradation rate by collagenase. For testing the angiogenic properties, non-modified and heparinized collagen specimens were--either loaded with VEGF or non-loaded--subcutaneously implanted on the back of rats. Specimens were explanted after varying periods of implantation, the dry weights and the hemoglobin contents, as well as immunostained histological sections were evaluated: heparinized collagen matrices loaded with VEGF are vascularized to a substantially higher extent as compared to non-modified matrices. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15812146     DOI: 10.1159/000083730

Source DB:  PubMed          Journal:  Cells Tissues Organs        ISSN: 1422-6405            Impact factor:   2.481


  7 in total

1.  Improved growth factor directed vascularization into fibrin constructs through inclusion of additional extracellular molecules.

Authors:  J D Smith; M E Melhem; K T Magge; A S Waggoner; P G Campbell
Journal:  Microvasc Res       Date:  2007-01-16       Impact factor: 3.514

Review 2.  Vascularization strategies for tissue engineering.

Authors:  Michael Lovett; Kyongbum Lee; Aurelie Edwards; David L Kaplan
Journal:  Tissue Eng Part B Rev       Date:  2009-09       Impact factor: 6.389

3.  Improving the angiogenic potential of collagen matrices by covalent incorporation of Astragalus polysaccharides.

Authors:  Chang Yao; Aiping Li; Weiwei Gao; Norbert Pallua; Guy Steffens
Journal:  Int J Burns Trauma       Date:  2011-09-02

4.  Improvement in Blood Supply After "Heparin-Dextran" Therapy in Patients of Buerger's Disease with Critical Limb Ischemia.

Authors:  Sanand Bag; Arunanshu Behera; Niranjan Khandelwal; J R Bapuraj; Rakesh Kumar Vasishta
Journal:  Indian J Surg       Date:  2012-06-19       Impact factor: 0.656

5.  An implantable vascularized protein gel construct that supports human fetal hepatoblast survival and infection by hepatitis C virus in mice.

Authors:  Martha J Harding; Christin M Lepus; Thomas F Gibson; Benjamin R Shepherd; Scott A Gerber; Morven Graham; Frank X Paturzo; Christoph Rahner; Joseph A Madri; Alfred L M Bothwell; Brett D Lindenbach; Jordan S Pober
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

Review 6.  Pathological ventricular remodeling: mechanisms: part 1 of 2.

Authors:  Jana S Burchfield; Min Xie; Joseph A Hill
Journal:  Circulation       Date:  2013-07-23       Impact factor: 29.690

7.  Repair of Adult Mammalian Heart After Damages by Oral Intake of Gu Ben Pei Yuan San.

Authors:  Baiping Cui; Yufan Zheng; Xinyan Zhou; Jiaqi Zhu; Jiexian Zhuang; Qianqian Liang; Chen Xu; Wei Sheng; Guoying Huang; Lina Luan; Ning Sun
Journal:  Front Physiol       Date:  2019-05-22       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.